- SNY has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $69.7 million.
- SNY is up 3.2% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in SNY with the Ticky from Trade-Ideas. See the FREE profile for SNY NOW at Trade-Ideas More details on SNY: Sanofi researches, develops, and markets various therapeutic solutions. The stock currently has a dividend yield of 2.2%. SNY has a PE ratio of 27. Currently there are 3 analysts that rate Sanofi a buy, no analysts rate it a sell, and 3 rate it a hold. The average volume for Sanofi has been 1.4 million shares per day over the past 30 days. Sanofi has a market cap of $130.8 billion and is part of the health care sector and drugs industry. Shares are up 8.5% year-to-date as of the close of trading on Monday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Sanofi as a buy. Among the primary strengths of the company is its expanding profit margins over time. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Highlights from the ratings report include:
- The gross profit margin for SANOFI is rather high; currently it is at 61.71%. It has increased from the same quarter the previous year. Despite the strong results of the gross profit margin, SNY's net profit margin of 11.50% significantly trails the industry average.
- SANOFI's earnings per share declined by 25.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, SANOFI increased its bottom line by earning $2.01 versus $1.90 in the prior year. This year, the market expects an improvement in earnings ($3.16 versus $2.01).
- SNY, with its decline in revenue, underperformed when compared the industry average of 1.9%. Since the same quarter one year prior, revenues fell by 12.5%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
- In its most recent trading session, SNY has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. Looking ahead, although the push and pull of the overall market trend could certainly make a critical difference, we do not see any strong reason stemming from the company's fundamentals that would cause a continuation of last year's decline. In fact, the stock is now selling for less than others in its industry in relation to its current earnings.
- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Pharmaceuticals industry average. The net income has significantly decreased by 26.4% when compared to the same quarter one year ago, falling from $1,493.43 million to $1,098.80 million.
- You can view the full Sanofi Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.